Novo Nordisk A S annual net debt
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Net Debt Growth & History (NVO)
Novo Nordisk A S's net debt was kr113.07B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr113.07B | kr19.17B | +20.41% |
| 2024 | 2024-12-31 | kr93.90B | kr75.56B | +411.98% |
| 2023 | 2023-12-31 | kr18.34B | kr680.0M | +3.85% |
| 2022 | 2022-12-31 | kr17.66B | −kr2.40B | −11.94% |
| 2021 | 2021-12-31 | kr20.05B | kr18.25B | +1012.93% |
| 2020 | 2020-12-31 | kr1.80B | kr8.91B | — |
| 2019 | 2019-12-31 | −kr7.10B | — | — |
Novo Nordisk A S quarterly net debt
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr95.64B | kr14.81B | +18.32% |
| Q1 2026 | 2026-03-31 | kr125.25B | — | — |
| Q4 2025 | 2025-12-31 | kr113.07B | kr19.17B | +20.41% |
| Q3 2025 | 2025-09-30 | kr69.13B | — | — |
| Q2 2025 | 2025-06-30 | kr80.83B | — | — |
| Q4 2024 | 2024-12-31 | kr93.90B | kr75.56B | +411.98% |
| Q4 2023 | 2023-12-31 | kr18.34B | kr680.0M | +3.85% |
| Q4 2022 | 2022-12-31 | kr17.66B | −kr2.40B | −11.94% |
| Q4 2021 | 2021-12-31 | kr20.05B | — | — |
Novo Nordisk A S net debt trends
Over the last five fiscal years, Novo Nordisk A S's net debt increased from kr1.80B to kr113.07B, a change of kr111.26B. The latest reported quarter, Q2 2026, shows kr95.64B.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...